Literature DB >> 19692904

Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting.

Maunank Shah1, Ebrahim Variava, Charles B Holmes, Alison Coppin, Jonathan E Golub, Jeremy McCallum, Michelle Wong, Binu Luke, Desmond J Martin, Richard E Chaisson, Susan E Dorman, Neil A Martinson.   

Abstract

BACKGROUND: Effective tuberculosis (TB) control in HIV-prevalent settings is hindered by absence of accurate, rapid TB diagnostic tests. We evaluated the accuracy of a urine lipoarabinomannan (LAM) test for TB diagnosis in South Africa.
METHODS: Hospitalized adults with signs and/or symptoms of active TB were enrolled. Sputum smear microscopy and mycobacterial culture, mycobacterial blood culture, and HIV testing were performed. A spot urine specimen was tested for LAM.
RESULTS: Four hundred ninety nine participants were enrolled; 422 (84.6%) were HIV infected. In microbiologically confirmed TB patients, the LAM test was positive in 114 of 193 [sensitivity 59%, (95% confidence interval: 52 to 66)], including 112 of 167 [67% (59 to 74)] who were HIV infected. Among individuals classified as "not TB", the LAM test was negative in 117 of 122 [specificity 96% (91 to 99)], including 83 of 88 [94% (87 to 98)] who were HIV infected. In confirmed TB patients, the LAM test was more sensitive than sputum smear microscopy (42%, 82 of 193, P < 0.001) and detected 56% (62 of 111) of those who were sputum smear negative. HIV infection [adjusted odds ratio (AOR 13.4)], mycobacteremia (AOR 3.21), and positive sputum smear (AOR 2.42) were risk factors for a positive LAM test.
CONCLUSIONS: The urine LAM test detected a subset of HIV-infected patients with severe TB in whom sputum smear microscopy had suboptimal sensitivity. The combination of urine LAM testing and sputum smear microscopy is attractive for use in settings with high HIV burden.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19692904      PMCID: PMC2815254          DOI: 10.1097/QAI.0b013e3181b98430

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

1.  Development of antigen detection assay for diagnosis of tuberculosis using sputum samples.

Authors:  L M Pereira Arias-Bouda; L N Nguyen; L M Ho; S Kuijper; H M Jansen; A H Kolk
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis.

Authors:  C Boehme; E Molokova; F Minja; S Geis; T Loscher; L Maboko; V Koulchin; M Hoelscher
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-08-31       Impact factor: 2.184

3.  Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis.

Authors:  D W Dowdy; M A O'Brien; D Bishai
Journal:  Int J Tuberc Lung Dis       Date:  2008-09       Impact factor: 2.373

4.  Clinical applications of the radioimmunoassay of secretory tuberculoprotein.

Authors:  E Straus; N Wu; M A Quraishi; S Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

5.  Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine.

Authors:  B Hamasur; J Bruchfeld; M Haile; A Pawlowski; B Bjorvatn; G Källenius; S B Svenson
Journal:  J Microbiol Methods       Date:  2001-05       Impact factor: 2.363

6.  Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre.

Authors:  T A Tessema; B Hamasur; G Bjun; S Svenson; B Bjorvatn
Journal:  Scand J Infect Dis       Date:  2001

Review 7.  Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes.

Authors:  Haileyesus Getahun; Mark Harrington; Rick O'Brien; Paul Nunn
Journal:  Lancet       Date:  2007-06-16       Impact factor: 79.321

Review 8.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

Authors:  Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye
Journal:  Arch Intern Med       Date:  2003-05-12

9.  Detection of mycobacterial antigens in cerebrospinal fluid of patients with tuberculous meningitis by enzyme-linked immunosorbent assay.

Authors:  E Sada; G M Ruiz-Palacios; Y López-Vidal; S Ponce de León
Journal:  Lancet       Date:  1983-09-17       Impact factor: 79.321

10.  Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.

Authors:  Stephen D Lawn; David J Edwards; Katharina Kranzer; Monica Vogt; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

View more
  66 in total

1.  Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis.

Authors:  Maunank Shah; Neil A Martinson; Richard E Chaisson; Desmond J Martin; Ebrahim Variava; Susan E Dorman
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

Review 2.  Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis.

Authors:  L L Flores; K R Steingart; N Dendukuri; I Schiller; J Minion; M Pai; A Ramsay; M Henry; S Laal
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

3.  High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay.

Authors:  Stephen D Lawn; Andrew D Kerkhoff; Monica Vogt; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

Review 4.  Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults.

Authors:  Maunank Shah; Colleen Hanrahan; Zhuo Yu Wang; Nandini Dendukuri; Stephen D Lawn; Claudia M Denkinger; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2016-05-10

Review 5.  Towards a point-of-care test for active tuberculosis: obstacles and opportunities.

Authors:  Ruth McNerney; Peter Daley
Journal:  Nat Rev Microbiol       Date:  2011-03       Impact factor: 60.633

6.  Tuberculosis screening in patients starting antiretroviral therapy in sub-Saharan Africa: stretching diagnostics to the limits.

Authors:  Stephen D Lawn; Robin Wood
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 7.  South African guideline for the management of community-acquired pneumonia in adults.

Authors:  Tom H Boyles; Adrian Brink; Greg L Calligaro; Cheryl Cohen; Keertan Dheda; Gary Maartens; Guy A Richards; Richard van Zyl Smit; Clifford Smith; Sean Wasserman; Andrew C Whitelaw; Charles Feldman
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 8.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

9.  Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.

Authors:  Keertan Dheda; Virginia Davids; Laura Lenders; Teri Roberts; Richard Meldau; Daphne Ling; Laurence Brunet; Richard van Zyl Smit; Jonathan Peter; Clare Green; Motasim Badri; Leonardo Sechi; Surendra Sharma; Michael Hoelscher; Rodney Dawson; Andrew Whitelaw; Jonathan Blackburn; Madhukar Pai; Alimuddin Zumla
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

10.  Changing concepts of "latent tuberculosis infection" in patients living with HIV infection.

Authors:  Stephen D Lawn; Robin Wood; Robert J Wilkinson
Journal:  Clin Dev Immunol       Date:  2010-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.